Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/4/2019 |
| Start Date: | November 22, 2017 |
| End Date: | April 10, 2018 |
Qualitative Research to Explore Patient Preference for Modes of Administration in Pulmonary Arterial Hypertension Treatments
GlaxoSmithKline (GSK) is embarking on a clinical program to assess the treatment of PAH with
an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous
administration, in comparison to current treatments which are taken orally. Hence, GSK would
like to conduct this qualitative interview study with PAH subjects to explore subject's
perspective and preferences for various modes of treatment administration (daily or weekly
subcutaneous injection versus current treatment options). This will be a qualitative study
comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to
10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).
an Angiotensin converting enzyme 2 (ACE2). This new treatment may require subcutaneous
administration, in comparison to current treatments which are taken orally. Hence, GSK would
like to conduct this qualitative interview study with PAH subjects to explore subject's
perspective and preferences for various modes of treatment administration (daily or weekly
subcutaneous injection versus current treatment options). This will be a qualitative study
comprising the conduct of semi-structured telephone concept elicitation interviews with 8 to
10 PAH subjects (each approximately 30 minutes in duration) in the United States (US).
Inclusion Criteria:
- Male or female, at least 18 years of age.
- Subject is willing and able to provide written informed consent.
- Subject must have a diagnosis of symptomatic Pulmonary Arterial Hypertension Type I as
per the World Health Organization (WHO) clinical classification system.
- Subject must have the cognitive and linguistic capabilities sufficient to allow them
to actively participate in an interview lasting 30 minutes.
Exclusion Criteria:
- Subject has a diagnosis of other cardiac or pulmonary disease.
- Subject has a Type II-V diagnosis of PAH, as per the WHO clinical classification
system.
- Subject is currently receiving treatment for PAH via modes of administration other
than intravenously or orally.
We found this trial at
1
site
Click here to add this to my saved trials
